← Back to Search

Artificial Heart

Total Artificial Heart for Heart Failure

N/A
Recruiting
Research Sponsored by BiVACOR Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Biventricular failure with at least two of the following hemodynamic and/or echocardiographic measurements.
Tricuspid insufficiency grade 4
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months or time of heart transplant (if prior to 6 months post pump implant)
Awards & highlights

Summary

"This trial will test if the BiVACOR Total Artificial Heart System can help adult patients with severe heart failure who need mechanical circulatory support to stay alive. The study will evaluate the safety and performance

Who is the study for?
This trial is for adults with severe heart failure who need mechanical support to survive and are waiting for a heart transplant. They must have specific heart function measurements like low right ventricular ejection fraction or high central venous pressure, indicating advanced heart issues.
What is being tested?
The study tests the BiVACOR Total Artificial Heart (TAH) System as a temporary solution for patients with severe biventricular or univentricular heart failure until they can get a transplant. It checks if the device is safe and works well in supporting their circulatory system.
What are the potential side effects?
While not explicitly listed, side effects may include complications related to device implantation, such as bleeding, infection, blood clots leading to stroke or other problems, and potential malfunction of the artificial heart system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My heart's two main chambers aren't working well.
Select...
I have severe tricuspid valve leakage.
Select...
My heart condition does not improve with treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months or time of heart transplant (if prior to 6 months post pump implant)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months or time of heart transplant (if prior to 6 months post pump implant) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility Endpoint
Safety Endpoint

Trial Design

1Treatment groups
Experimental Treatment
Group I: BiVACOR TAHExperimental Treatment1 Intervention
The BiVACOR TAH System will be implanted as a bridge to transplant (BTT) for adults with severe irreversible biventricular heart failure or univentricular heart failure in which LVAD support is not recommended, and who are eligible for cardiac transplantation.

Find a Location

Who is running the clinical trial?

BiVACOR Inc.Lead Sponsor
~3 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top